Drugs / Alisporivir
Trials 13 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02753699 Background | Dec 2011 → May 2015 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alisporivir | “Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to...” NCT01318694 ↗ |
| Known as | (d-meala)3-(etval)4-csa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651956 ↗ |
| Known as | ALV | “This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin...” NCT01500772 ↗1“This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African...” NCT01446250 ↗ |
| Known as | DEB025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02173574 ↗ |
| Known as | Debio 025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00854802 ↗ |
| Known as | UNIL 025 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651956 ↗ |
| Action | Inhibit | “Cyclophilin A inhibitor” CHEMBL1651956 ↗1“cyclophilin inhibitor” NCT00537407 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1651956 ↗ |
| Route | Oral | “Debio 025 (alisporivir) 400 mg orally once daily” NCT00537407 ↗ |
| Target | PPIA | “Cyclophilin A inhibitor” CHEMBL1651956 ↗ |